CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...
Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...
However, overall revenues fell short of expectations at $13.5 million. The discontinuation of enrollment in its ongoing phase ...
On September 25, 2024, 2seventy bio issued a press release announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ...
On September 25, 2024, 2seventy bio issued a press release announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel ...
The decision to discontinue enrollment in the KarMMa-9 study is an example of the kind of financial discipline we will continue to apply across the business. Together with BMS, we are looking ...
This follows the discontinuation of the KarMMa-9 trial which was expected to contribute significantly to revenue growth. Despite this, the company, in collaboration with its partner, is expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback